Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

[Proef met een apparaat dat niet is goedgekeurd of goedgekeurd door de Amerikaanse FDA] (INNOVATE)

3 november 2026 bijgewerkt door: BrioHealth Solutions, Inc.

The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

Studie Overzicht

Toestand

Actief, niet wervend

Gedetailleerde beschrijving

The INNOVATE Trial is a prospective, non-blinded, randomized, controlled, multi-center, non-inferiority study to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3™ (HM3) LVAS (Abbott) when used for the treatment of advanced, refractory left ventricular heart failure. It is the first clinical study to compare two left ventricular assist devices (LVAD) that belong to the same category of fully magnetically levitated LVAD.

Studietype

Ingrijpend

Inschrijving (Geschat)

780

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • University of Alabama at Birmingham Hospital
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72205
        • Baptist Health Medical Center-Little Rock
    • California
      • Los Angeles, California, Verenigde Staten, 90048
        • Cedars-Sinai Medical Center
    • Florida
      • Gainsville, Florida, Verenigde Staten, 32608
        • UF Health Shands Hospital
      • Orlando, Florida, Verenigde Staten, 32803
        • Advent Health
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Emory University
      • Atlanta, Georgia, Verenigde Staten, 30309
        • Piedmont Healthcare
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Northwestern University
      • Chicago, Illinois, Verenigde Staten, 60637
        • University of Chicago
      • Chicago, Illinois, Verenigde Staten, 60453
        • Advocate Christ Medical Center
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46260
        • Ascension St. Vincent Hospital - Indianapolis
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • The University Of Kansas Medical Center
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40536
        • University of Kentucky
      • Louisville, Kentucky, Verenigde Staten, 40202
        • University of Louisville
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21201
        • University of Maryland Medical Center
      • Baltimore, Maryland, Verenigde Staten, 21287
        • The Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Verenigde Staten, 02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • University of Michigan
      • Detriot, Michigan, Verenigde Staten, 48202
        • Henry Ford Health
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Corewell Health Grand Rapids Hospital
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55455
        • University of Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Abbott Northwestern Hospital
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • WashU Medicine
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68198
        • University of Nebraska Medical Center
    • New Jersey
      • Newark, New Jersey, Verenigde Staten, 07112
        • Newark Beth Israel Medical Center
    • New York
      • New York, New York, Verenigde Staten, 10065
        • Weill Cornell Medicine
      • New York, New York, Verenigde Staten, 10016
        • NYU Langone Health
      • New York, New York, Verenigde Staten, 10029
        • Mount Sinai
      • New York, New York, Verenigde Staten, 10032
        • Columbia University Irving Medical Center/ New York Presbyterian Hospital
      • The Bronx, New York, Verenigde Staten, 10467
        • Montefiore Medical Center
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27710
        • Duke University
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • The Christ Hospital - Cincinnati
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19107
        • Thomas Jefferson University Hospital
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Medical University of South Carolina
    • Tennessee
      • Memphis, Tennessee, Verenigde Staten, 38120
        • Baptist - Memphis (Stern)
    • Texas
      • Dallas, Texas, Verenigde Staten, 75246
        • Baylor University Medical Center, part of Baylor Scott & White Health
      • Dallas, Texas, Verenigde Staten, 75390
        • UT southwestern Medical Center
      • Houston, Texas, Verenigde Staten, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Verenigde Staten, 77030
        • Memorial Hermann-Texas Medical Center
      • Houston, Texas, Verenigde Staten, 77030
        • Texas Heart Institute at Baylor St. Luke's Medical Center
      • Plano, Texas, Verenigde Staten, 75093
        • Baylor Scott & White Medical Center - Plano
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84132
        • University of Utah
    • Virginia
      • Falls Church, Virginia, Verenigde Staten, 22042
        • Inova Fairfax Medical Campus
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53215
        • Aurora St. Luke's Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 100 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Patient is ≥ 18 years of age.

  2. Patient has received institutional approval for LVAD implantation.

  3. Patient has a body surface area (BSA) ≥ 1.2 m2.

  4. Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.

  5. Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF < 30% on inotropes or temporary MCS.

  6. Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:

    1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
    2. Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or temporary mechanical circulatory support device (MCSD) for at least seven days.
  7. Patient has provided voluntary and informed consent.

  8. Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.

Exclusion Criteria:

  1. Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.

  2. Patient had a myocardial infarction within seven days of study enrollment.

  3. Patient had cardiothoracic surgery within 30 days of implant with the exception of a procedure to implant temporary MCS: Impella 5.5, Impella CP or TandemHeart.

  4. Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.

  5. Patient has contraindications to warfarin anticoagulation.

  6. Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.

  7. Patient is on durable MCS (e.g., LVAD or RVAD).

  8. Planned need for durable or temporary RVAD support concomitant with LVAD implant.

  9. Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an intra-aortic balloon pump, Impella 5.5, Impella CP, or TandemHeart.

  10. Patient is on any form of pre-implant temporary MCS and has a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or plasma free hemoglobin > 40 g/dL.

  11. Patient has a history of organ transplantation.

  12. Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.

  13. Patient has a platelet count < 50 k/μl.

  14. Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.

  15. Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.

  16. Patient has an uncontrolled systemic infection.

  17. Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.

  18. Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:

    1. Total bilirubin > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.
    2. International normalized ratio (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
    3. Glomerular filtration rate (GFR) < 30 mL/ min/1.73 m2 or need for renal replacement therapy.
    4. Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
    5. Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1/FVC < 0.7 and FEV1 < 40% predicted.
    6. Mechanical ventilation for more than three days present at the time of study enrollment.
    7. Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
    8. History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
    9. Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
    10. Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
    11. Pre-albumin < 15 mg/dL and/or albumin < 2.5 g/dL.
  19. Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.

  20. Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.

  21. Patient is participating in an interventional clinical trial that may impact or confound the results of the INNOVATE Trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: BrioVAD System

BrioVAD® Left Ventricular Assist System (BrioVAD® System) by BrioHealth Solutions, Inc.

Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.

Actieve vergelijker: HeartMate 3

HeartMate 3 System by Abbott

Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Short-Term Indication Primary Endpoint
Tijdsspanne: 6 months

Composite of survival to transplant, recovery or 6 months of LVAD support free of debilitating stroke [modified Rankin Scale (mRS) > 3], or reoperation to replace the pump

6 months
Long-Term Indication Primary Endpoint
Tijdsspanne: 24 months

Composite of survival to transplant, recovery or 24 months of LVAD support free of debilitating stroke (mRS > 3), or reoperation to replace the pump.

24 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Powered Secondary Endpoint
Tijdsspanne: 24 months

Total number of nights in hospital, skilled nursing facility, or inpatient rehabilitation, inclusive of index hospitalization, through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first.

24 months
Short-Term Indication Secondary Endpoint
Tijdsspanne: 6 months

Evaluation of the short-term safety using INTERMACS adverse event (AE) terms and definitions through 6 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 6 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. Serious adverse events (SAEs) will be analyzed in a similar manner.

6 months
Long-Term Indication Secondary Endpoint
Tijdsspanne: 24 months

Evaluation of the long-term safety using INTERMACS AE terms and definitions through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 24 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. SAEs will be analyzed in a similar manner

24 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

28 oktober 2024

Primaire voltooiing (Geschat)

1 februari 2028

Studie voltooiing (Geschat)

1 december 2028

Studieregistratiedata

Eerst ingediend

7 maart 2024

Eerst ingediend dat voldeed aan de QC-criteria

7 maart 2024

Eerst geplaatst (Werkelijk)

13 maart 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

3 november 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Protocol and data is company confidential.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren